SciSparc Ltd. (NASDAQ: SPRC) 宣布,其合资公司Neurothera Labs已获得美国专利商标局授予的一项关键专利。该专利涵盖了一种基于大麻素化合物的创新技术,旨在有效对抗包括耐甲氧西林金黄色葡萄球菌(MRSA)在内的抗菌素耐药性感染。
这一突破性技术通过独特的大麻素配方增强抗生素疗效,为解决全球公共卫生危机提供了新思路。专利授权将进一步巩固SciSparc在神经科学与大麻素药物开发领域的技术壁垒,为后续商业化应用奠定基础。
SciSparc Ltd. (NASDAQ: SPRC) 宣布,其合资公司Neurothera Labs已获得美国专利商标局授予的一项关键专利。该专利涵盖了一种基于大麻素化合物的创新技术,旨在有效对抗包括耐甲氧西林金黄色葡萄球菌(MRSA)在内的抗菌素耐药性感染。
这一突破性技术通过独特的大麻素配方增强抗生素疗效,为解决全球公共卫生危机提供了新思路。专利授权将进一步巩固SciSparc在神经科学与大麻素药物开发领域的技术壁垒,为后续商业化应用奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.